Description Format Details Value
Advanced-stage ovarian cancer patients are generally treated with platinum/taxane-based chemotherapy after primary debulking surgery. However, there is a wide range of outcomes for individual patients. Therefore, the clinicopathological factors alone are insufficient for predicting prognosis. Our aim is to identify a progression-free survival (PFS)-related molecular profile for predicting survival of patients with advanced-stage serous ovarian cancer.Advanced-stage serous ovarian cancer tissues from 110 Japanese patients who underwent primary surgery and platinum/taxane-based chemotherapy were profiled using oligonucleotide microarrays. We selected 88 PFS-related genes by a univariate Cox model (p<0.01) and generated the prognostic index based on 88 PFS-related genes after adjustment of regression coefficients of the respective genes by ridge regression Cox model using 10-fold cross-validation. The prognostic index was independently associated with PFS time compared to other clinical factors in multivariate analysis [hazard ratio (HR), 3.72; 95% confidence interval (CI), 2.66-5.43; p<0.0001]. In an external dataset, multivariate analysis revealed that this prognostic index was significantly correlated with PFS time (HR, 1.54; 95% CI, 1.20-1.98; p = 0.0008). Furthermore, the correlation between the prognostic index and overall survival time was confirmed in the two independent external datasets (log rank test, p = 0.0010 and 0.0008).The prognostic ability of our index based on the 88-gene expression profile in ridge regression Cox hazard model was shown to be independent of other clinical factors in predicting cancer prognosis across two distinct datasets. Further study will be necessary to improve predictive accuracy of the prognostic index toward clinical application for evaluation of the risk of recurrence in patients with advanced-stage serous ovarian cancer.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 | experimentData(eset):
Experiment data
Experimenter name: Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Kotera K, Masuzaki H, Tashiro H, Katabuchi H, Inoue I, Tanaka K.Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One. 2010 Mar 12; 5(3):e9615.
Laboratory: Yoshihara, Tanaka 2010
Contact information:
Title: Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
URL:
PMIDs: 20300634
Abstract: A 257 word abstract is available. Use 'abstract' method.
Information is available on: preprocessing
notes:
platform_title:
Agilent-012391 Whole Human Genome Oligo Microarray G4112A
platform_shorttitle:
Agilent G4112A
platform_summary:
hgug4112a
platform_manufacturer:
Agilent
platform_distribution:
commercial
platform_accession:
GPL6848
version:
2015-09-22 19:16:49
featureData(eset):
An object of class 'AnnotatedDataFrame'
featureNames: A_23_P100001 A_23_P100011 ... A_32_P99902 (30936 total)
varLabels: probeset gene EntrezGene.ID best_probe
varMetadata: labelDescription
|
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 | assayData: 30936 features, 110 samples
Platform type:
Overall survival time-to-event summary (in years):
Call: survfit(formula = Surv(time, cens) ~ -1)
n events median 0.95LCL 0.95UCL
110.00 46.00 4.44 4.03 NA
---------------------------
Available sample meta-data:
---------------------------
alt_sample_name:
Serous ovarian cancer 10 Serous ovarian cancer 100 Serous ovarian cancer 104
1 1 1
Serous ovarian cancer 106 Serous ovarian cancer 107 Serous ovarian cancer 108
1 1 1
Serous ovarian cancer 109 Serous ovarian cancer 11 Serous ovarian cancer 110
1 1 1
Serous ovarian cancer 111 Serous ovarian cancer 112 Serous ovarian cancer 113
1 1 1
Serous ovarian cancer 114 Serous ovarian cancer 115 Serous ovarian cancer 116
1 1 1
Serous ovarian cancer 117 Serous ovarian cancer 118 Serous ovarian cancer 119
1 1 1
Serous ovarian cancer 12 Serous ovarian cancer 120 Serous ovarian cancer 122
1 1 1
Serous ovarian cancer 123 Serous ovarian cancer 127 Serous ovarian cancer 129
1 1 1
Serous ovarian cancer 130 Serous ovarian cancer 131 Serous ovarian cancer 132
1 1 1
Serous ovarian cancer 134 Serous ovarian cancer 136 Serous ovarian cancer 137
1 1 1
Serous ovarian cancer 139 Serous ovarian cancer 140 Serous ovarian cancer 143
1 1 1
Serous ovarian cancer 144 Serous ovarian cancer 145 Serous ovarian cancer 146
1 1 1
Serous ovarian cancer 148 Serous ovarian cancer 149 Serous ovarian cancer 15
1 1 1
Serous ovarian cancer 150 Serous ovarian cancer 151 Serous ovarian cancer 154
1 1 1
Serous ovarian cancer 156 Serous ovarian cancer 157 Serous ovarian cancer 16
1 1 1
Serous ovarian cancer 160 Serous ovarian cancer 17 Serous ovarian cancer 171
1 1 1
Serous ovarian cancer 172 Serous ovarian cancer 173 Serous ovarian cancer 174
1 1 1
Serous ovarian cancer 176 Serous ovarian cancer 178 Serous ovarian cancer 18
1 1 1
Serous ovarian cancer 182 Serous ovarian cancer 183 Serous ovarian cancer 184
1 1 1
Serous ovarian cancer 185 Serous ovarian cancer 186 Serous ovarian cancer 2
1 1 1
Serous ovarian cancer 20 Serous ovarian cancer 22 Serous ovarian cancer 23
1 1 1
Serous ovarian cancer 25 Serous ovarian cancer 27 Serous ovarian cancer 31
1 1 1
Serous ovarian cancer 36 Serous ovarian cancer 37 Serous ovarian cancer 38
1 1 1
Serous ovarian cancer 4 Serous ovarian cancer 41 Serous ovarian cancer 42
1 1 1
Serous ovarian cancer 43 Serous ovarian cancer 44 Serous ovarian cancer 45
1 1 1
Serous ovarian cancer 49 Serous ovarian cancer 50 Serous ovarian cancer 51
1 1 1
Serous ovarian cancer 52 Serous ovarian cancer 53 Serous ovarian cancer 54
1 1 1
Serous ovarian cancer 55 Serous ovarian cancer 56 Serous ovarian cancer 57
1 1 1
Serous ovarian cancer 58 Serous ovarian cancer 6 Serous ovarian cancer 60
1 1 1
Serous ovarian cancer 61 Serous ovarian cancer 62 Serous ovarian cancer 64
1 1 1
Serous ovarian cancer 66 Serous ovarian cancer 67 Serous ovarian cancer 68
1 1 1
Serous ovarian cancer 69 Serous ovarian cancer 7 Serous ovarian cancer 72
1 1 1
Serous ovarian cancer 77 Serous ovarian cancer 79 Serous ovarian cancer 80
1 1 1
(Other)
11
sample_type:
tumor
110
histological_type:
ser
110
primarysite:
ov
110
summarygrade:
high low
43 67
summarystage:
late
110
tumorstage:
3 4
93 17
substage:
a b c NA's
6 18 69 17
grade:
1 2 3
26 41 43
pltx:
y
110
tax:
y
110
days_to_tumor_recurrence:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30.0 285.0 510.0 673.9 870.0 2250.0
recurrence_status:
norecurrence recurrence
34 76
days_to_death:
Min. 1st Qu. Median Mean 3rd Qu. Max.
30 660 915 1086 1530 2430
vital_status:
deceased living
46 64
debulking:
optimal suboptimal
57 53
uncurated_author_metadata:
title: Serous ovarian cancer 100///geo_accession: GSM432221///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 1///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432221/GSM432221.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 104///geo_accession: GSM432222///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 24///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432222/GSM432222.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 106///geo_accession: GSM432223///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432223/GSM432223.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795125
1
title: Serous ovarian cancer 107///geo_accession: GSM432224///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432224/GSM432224.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 108///geo_accession: GSM432225///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 37///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 37///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432225/GSM432225.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795126
1
title: Serous ovarian cancer 109///geo_accession: GSM432226///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 7///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 20///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432226/GSM432226.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795127
1
title: Serous ovarian cancer 10///geo_accession: GSM432220///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 55///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 55///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432220/GSM432220.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 110///geo_accession: GSM432228///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 60///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 60///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432228/GSM432228.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795128
1
title: Serous ovarian cancer 111///geo_accession: GSM432229///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 15 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 18///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 57///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432229/GSM432229.txt.gz///data_row_count: 41000///relation: Reanalyzed by: GSM795129
1
title: Serous ovarian cancer 112///geo_accession: GSM432230///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 48///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 48///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432230/GSM432230.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 113///geo_accession: GSM432231///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 43///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 69///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432231/GSM432231.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 114///geo_accession: GSM432232///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 27///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432232/GSM432232.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 115///geo_accession: GSM432233///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 69///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432233/GSM432233.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 116///geo_accession: GSM432234///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 51///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432234/GSM432234.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 117///geo_accession: GSM432235///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432235/GSM432235.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 118///geo_accession: GSM432236///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432236/GSM432236.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 119///geo_accession: GSM432237///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432237/GSM432237.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 11///geo_accession: GSM432227///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 46///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 47///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432227/GSM432227.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 120///geo_accession: GSM432239///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 6///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 52///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432239/GSM432239.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 122///geo_accession: GSM432240///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 25///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432240/GSM432240.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 123///geo_accession: GSM432242///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 22///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432242/GSM432242.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 127///geo_accession: GSM432243///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 23///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 53///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432243/GSM432243.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 129///geo_accession: GSM432244///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 13///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432244/GSM432244.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 12///geo_accession: GSM432238///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432238/GSM432238.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 130///geo_accession: GSM432245///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 25///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 79///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432245/GSM432245.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 131///geo_accession: GSM432246///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 74///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 74///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432246/GSM432246.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 132///geo_accession: GSM432247///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 75///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 75///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432247/GSM432247.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 134///geo_accession: GSM432248///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 30///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 62///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432248/GSM432248.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 136///geo_accession: GSM432249///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 64///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 64///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432249/GSM432249.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 137///geo_accession: GSM432250///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 46///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 46///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432250/GSM432250.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 139///geo_accession: GSM432251///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 35///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 44///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432251/GSM432251.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 140///geo_accession: GSM432252///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 28///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432252/GSM432252.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 143///geo_accession: GSM432253///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 6///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432253/GSM432253.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 144///geo_accession: GSM432254///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 31///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432254/GSM432254.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 145///geo_accession: GSM432255///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 24///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 28///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432255/GSM432255.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 146///geo_accession: GSM432256///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 24///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432256/GSM432256.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 148///geo_accession: GSM432257///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432257/GSM432257.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 149///geo_accession: GSM432258///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432258/GSM432258.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 150///geo_accession: GSM432260///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 14///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432260/GSM432260.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 151///geo_accession: GSM432261///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 13///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432261/GSM432261.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 154///geo_accession: GSM432262///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 9///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 9///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432262/GSM432262.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 156///geo_accession: GSM432263///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 29///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 29///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432263/GSM432263.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 157///geo_accession: GSM432264///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432264/GSM432264.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 15///geo_accession: GSM432259///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 18///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 49///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432259/GSM432259.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 160///geo_accession: GSM432266///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 16///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 20///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432266/GSM432266.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 16///geo_accession: GSM432265///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 49///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432265/GSM432265.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 171///geo_accession: GSM432268///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 3///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432268/GSM432268.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 172///geo_accession: GSM432269///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 12///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432269/GSM432269.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 173///geo_accession: GSM432270///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 5///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432270/GSM432270.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 174///geo_accession: GSM432271///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 23///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 41///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432271/GSM432271.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 176///geo_accession: GSM432272///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 11///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432272/GSM432272.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 178///geo_accession: GSM432273///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 47///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432273/GSM432273.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 17///geo_accession: GSM432267///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 47///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 47///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432267/GSM432267.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 182///geo_accession: GSM432275///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 1///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432275/GSM432275.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 183///geo_accession: GSM432276///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 72///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 72///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432276/GSM432276.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 184///geo_accession: GSM432277///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 65///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 65///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432277/GSM432277.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 185///geo_accession: GSM432278///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 20///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432278/GSM432278.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 186///geo_accession: GSM432279///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 29///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432279/GSM432279.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 18///geo_accession: GSM432274///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 50///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 50///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432274/GSM432274.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 20///geo_accession: GSM432281///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 70///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 70///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432281/GSM432281.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 22///geo_accession: GSM432282///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 15///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432282/GSM432282.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 23///geo_accession: GSM432283///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 8///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432283/GSM432283.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 25///geo_accession: GSM432284///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 29///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 80///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432284/GSM432284.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 27///geo_accession: GSM432285///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 11///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432285/GSM432285.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 2///geo_accession: GSM432280///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 18///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 49///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432280/GSM432280.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 31///geo_accession: GSM432286///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 5///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432286/GSM432286.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 36///geo_accession: GSM432287///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 23///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 28///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432287/GSM432287.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 37///geo_accession: GSM432288///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 21///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 25///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432288/GSM432288.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 38///geo_accession: GSM432289///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 15///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 64///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432289/GSM432289.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 41///geo_accession: GSM432291///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 61///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 61///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432291/GSM432291.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 42///geo_accession: GSM432292///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 17///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 46///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432292/GSM432292.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 43///geo_accession: GSM432293///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 7///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 34///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432293/GSM432293.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 44///geo_accession: GSM432294///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 4///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 17///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432294/GSM432294.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 45///geo_accession: GSM432295///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 35///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 39///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432295/GSM432295.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 49///geo_accession: GSM432296///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 33///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 37///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432296/GSM432296.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 4///geo_accession: GSM432290///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 2///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 41///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432290/GSM432290.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 50///geo_accession: GSM432297///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 8///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 33///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432297/GSM432297.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 51///geo_accession: GSM432298///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 25///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432298/GSM432298.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 52///geo_accession: GSM432299///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 4///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 24///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432299/GSM432299.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 53///geo_accession: GSM432300///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 9///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 23///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432300/GSM432300.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 54///geo_accession: GSM432301///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 30///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 30///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432301/GSM432301.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 55///geo_accession: GSM432302///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 30///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 30///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432302/GSM432302.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 56///geo_accession: GSM432303///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 14///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 29///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432303/GSM432303.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 57///geo_accession: GSM432304///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 23///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432304/GSM432304.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 58///geo_accession: GSM432305///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 20///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432305/GSM432305.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 60///geo_accession: GSM432307///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IV///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 47///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 81///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432307/GSM432307.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 61///geo_accession: GSM432308///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 74///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432308/GSM432308.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 62///geo_accession: GSM432309///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 11///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432309/GSM432309.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 64///geo_accession: GSM432310///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 26///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432310/GSM432310.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 66///geo_accession: GSM432311///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 19///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 19///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432311/GSM432311.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 67///geo_accession: GSM432312///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 22///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 22///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432312/GSM432312.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 68///geo_accession: GSM432313///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 22///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 22///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432313/GSM432313.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 69///geo_accession: GSM432314///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 21///characteristics_ch1.4: recurrence (1): 0///characteristics_ch1.5: overall survival (m): 21///characteristics_ch1.6: death (1): 0///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432314/GSM432314.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 6///geo_accession: GSM432306///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 32///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432306/GSM432306.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 72///geo_accession: GSM432316///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIb///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 13///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 26///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432316/GSM432316.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 77///geo_accession: GSM432317///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 3///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 1///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 1///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432317/GSM432317.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 79///geo_accession: GSM432318///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 16///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 27///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432318/GSM432318.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 7///geo_accession: GSM432315///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 1///characteristics_ch1.1: Stage: IIIa///characteristics_ch1.2: cytoreductive surgery: optimal///characteristics_ch1.3: progression-free survival (m): 19///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 42///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432315/GSM432315.txt.gz///data_row_count: 41000///relation:
1
title: Serous ovarian cancer 80///geo_accession: GSM432319///status: Public on Mar 22 2010///submission_date: Jul 22 2009///last_update_date: Sep 13 2011///type: RNA///channel_count: 1///source_name_ch1: serous ovarian cancer///organism_ch1: Homo sapiens///characteristics_ch1: tumor grade: 2///characteristics_ch1.1: Stage: IIIc///characteristics_ch1.2: cytoreductive surgery: not optimal///characteristics_ch1.3: progression-free survival (m): 12///characteristics_ch1.4: recurrence (1): 1///characteristics_ch1.5: overall survival (m): 68///characteristics_ch1.6: death (1): 1///characteristics_ch1.7: disease state: serous ovarian cancer///characteristics_ch1.8: tissue: cancer tumor///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was extracted from tissue samples using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's recommendations. RNA was examined with a 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) using an RNA 6000 Nano LabChip (Agilent Technologies)///label_ch1: Cy3///label_protocol_ch1: Cyanine-3 (Cy3) labeled cRNA was prepared from 0.5 ug RNA using the Quick Amp Labering Kit, one-color (Agilent Technologies) according to the manufacturer's instructions, followed by RNAeasy column purification (QIAGEN, Valencia, CA).///taxid_ch1: 9606///hyb_protocol: Cy3-labeled cRNAs (1.65 g) were hybridized for 17 hours at 65C to an Agilent Whole Human Genome Oligo Microarray in a rotating Agilent hybridization oven.///scan_protocol: The hybridized microarray was washed and then scanned in Cy3 channel with the Agilent DNA Microarray Scanner (model G2565AA).///description: n/a///data_processing: Signal intensity per spot was generated from the scanned image with Feature Extraction Software ver8.5 (Agilent Technologies) in the default settings. Data normalization was performed in GeneSpring GX 10 (Agilent Technologies) as follows: (i) Threshold raw signals were set to 1.0. (ii) Quantile normalization was chosen as normalized algorithm. (iii) Baseline was transformed to median of all samples.///platform_id: GPL6480///contact_name: Kosuke,,Yoshihara///contact_email: yoshikou@med.niigata-u.ac.jp///contact_department: Obstetrics and Gynecology///contact_institute: Niigata University///contact_address: 1-757 Asahimachi-dori///contact_city: Niigata///contact_zip.postal_code: 951-8510///contact_country: Japan///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM432nnn/GSM432319/GSM432319.txt.gz///data_row_count: 41000///relation:
1
(Other)
11
|
An expression set
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.